Business
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio’s proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company’s pipeline of innovative immuno
About this update from Tevogen Bio Holdings Inc.
[{"type":"image","alt":"Tevogen Bio Inc","displaySize":"","headline":null,"caption":"Tevogen Bio Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/5d67b8c6f92b49048a1dc80d97a6164f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kuP3e9ZLQ.FWmrA1GfPG6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5d67b8c6f92b49048a1dc80d97a6164f","width":300,"height":157}},"lazy":false},{"type":"text","content":"WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™.","length":222,"tagName":"p"},{"type":"text","content":"Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio’s proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company’s pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs.","length":366,"tagName":"p"},{"type":"text","content":"Tevogen.AI currently has two proprietary technologies, each with patents pending, and an internal valuation of these assets is forthcoming. The Company plans to expand its AI initiative with applications that extend well beyond Tevogen Bio. In preparation for this anticipated growth, Tevogen is expanding its headquarters to include dedicated facilities for Tevogen.AI’s team of data scientists and engineers.","length":410,"tagName":"p"},{"type":"text","content":"Tevogen CEO, Dr. Ryan Saadi, commented, “Healthcare is one of the largest segments of our economy, projected to approach $5 trillion in the U.S. in 2025 and a significant contributor to our rising national debt. Tevogen.AI’s vision extends beyond transforming how therapies are developed; it is expected to make a meaningful impact across multiple sectors of healthcare. I applaud the leadership team at Tevogen.AI and our strategic partners for their innovative efforts and contributions that will help define the future of healthcare.”","length":537,"tagName":"p"},{"type":"text","content":"Strategic Partnerships:","length":23,"tagName":"p"},{"type":"text","content":"Microsoft (...